Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window (ImpACT-24)
This study is currently recruiting participants.
Verified June 2013 by BrainsGate
Sponsor:
BrainsGate
Information provided by (Responsible Party):
BrainsGate
ClinicalTrials.gov Identifier:
NCT00826059
First received: January 19, 2009
Last updated: June 6, 2013
Last verified: June 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The primary objective of the study is to assess the safety and effectiveness of SPG stimulation with the ISS in patients with an acute ischemic stroke in the anterior circulation initiated within 24 hours from stroke onset.
| Condition | Intervention | Phase |
|---|---|---|
|
Ischemic Stroke |
Device: The Ischemic Stroke System Device: Sham control |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A Multicenter, Randomized, Double Blind, Sham Control, Parallel Arm Trial to Assess Effectiveness and Safety of the Ischemic Stroke System ISS, as an Adjunct to Standard of Care in Subjects With Acute Ischemic Stroke |
Further study details as provided by BrainsGate:
Primary Outcome Measures:
- Distribution of patients across the ordinal modified Rankin scale (mRS) [ Time Frame: 90 days ] [ Designated as safety issue: No ]
The primary effectiveness endpoint will be the modified Rankin Scale (mRS) evaluated by the site on Day 90±7.
The statistical analysis of the primary effectiveness endpoint will be: Sliding Dichotomous mRS.
Secondary Outcome Measures:
- Sliding Dichotomous mRS for subjects with aphasia at baseline [ Time Frame: 90 days ] [ Designated as safety issue: No ]
- Binary NIHSS (success for score ≤ 1 or for ≥ 9-point improvement versus baseline) [ Time Frame: 90 days ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 450 |
| Study Start Date: | January 2009 |
| Estimated Study Completion Date: | July 2014 |
| Estimated Primary Completion Date: | July 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Active Stimulation |
Device: The Ischemic Stroke System
SPG stimulation and standard of care
|
| Sham Comparator: Sham Stimulation |
Device: Sham control
Sham stimulation and standard of care
|
Eligibility| Ages Eligible for Study: | 40 Years to 85 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Age: Between 40 years and 80 years for male and 85 for female subjects
- Clinical diagnosis of an acute ischemic stroke in the Carotid, Middle or Anterior Cerebral Artery territories
- Imaging findings demonstrating signs of ischemia in the anterior circulation, consistent with the clinical diagnosis
- Baseline NIHSS ≥ 7 and ≤ 18 within 2 hours prior to implantation.
- Ability to initiate treatment within 8- 24 hours from stroke onset
- Signed informed consent from patient him/herself or legally authorized representative if applicable
Exclusion Criteria:
- Intracranial hemorrhage or hemorrhagic transformation
- Massive stroke
- Acute ischemic stroke in the posterior circulation
- Minor stroke
- Treated with IV-tPA ,IA-tPA or neurothrombectomy devices for the current stroke
- Previous stroke in the last 6 months or pre-existing disability
- Patients with bleeding propensity or any condition in the oral cavity that prevents implantation
- Clinical signs and symptoms or imaging evidence of bilateral stroke.
- Treated with IV-tPA ,IA-tPA or neurothrombectomy devices for the current stroke.
- Known cerebral arteriovenous malformation, cerebral aneurysm.
- Clinical suspicion of septic embolus.
- Uncontrolled hypertension (systolic >185 mmHg and/or diastolic >110 mmHg)
- Serious systemic infection.
- Women known to be pregnant or having a positive or indeterminate pregnancy test.
- Patients with other implanted neural stimulator/ electronic devices (pacemakers).
- Life expectancy < 1 year from causes other than stroke.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00826059
Contacts
| Contact: Noam Zilberman | noamz@brainsgate.com |
Locations
| United States, Florida | |
| Intercoastal Medical Group | Recruiting |
| Sarasota, Florida, United States, 34232 | |
| United States, Illinois | |
| Central DuPage Hospital | Recruiting |
| Winfield, Illinois, United States, 60190 | |
| United States, Massachusetts | |
| UMASS Medical Center | Recruiting |
| Worcester, Massachusetts, United States, 01655 | |
| United States, Ohio | |
| ProMedica Toledo Hospital | Recruiting |
| Toledo, Ohio, United States, 43606 | |
| United States, South Carolina | |
| Palmetto Health Richland | Recruiting |
| Columbia, South Carolina, United States, 29203 | |
| United States, Tennessee | |
| Erlanger Stroke Center | Recruiting |
| Chattanooga, Tennessee, United States, 37404 | |
| United States, Texas | |
| The Methodist Hospital System | Recruiting |
| Houston, Texas, United States, 77030 | |
| Germany | |
| Erlangen University Clinic | Recruiting |
| Erlangen, Germany | |
| Essen University Clinic | Recruiting |
| Essen, Germany | |
| Heidelberg University Clinic | Recruiting |
| Heidelberg, Germany | |
| Leipzig University Clinic | Recruiting |
| Leipzig, Germany | |
| Spain | |
| Hospital Vall d'Hebron | Recruiting |
| Barcelona, Spain | |
Sponsors and Collaborators
BrainsGate
More Information
No publications provided
| Responsible Party: | BrainsGate |
| ClinicalTrials.gov Identifier: | NCT00826059 History of Changes |
| Other Study ID Numbers: | CLP1000500 |
| Study First Received: | January 19, 2009 |
| Last Updated: | June 6, 2013 |
| Health Authority: | United States: Food and Drug Administration Germany: Ethics Commission Spain: Agencia Española de Medicamentos y Productos Sanitarios |
Keywords provided by BrainsGate:
|
acute ischemic stroke randomized clinical trial effectiveness safety |
Additional relevant MeSH terms:
|
Ischemia Stroke Cerebral Infarction Pathologic Processes Cerebrovascular Disorders Brain Diseases |
Central Nervous System Diseases Nervous System Diseases Vascular Diseases Cardiovascular Diseases Brain Infarction Brain Ischemia |
ClinicalTrials.gov processed this record on June 18, 2013